Diabetic Foot News and Research

RSS
SANUWAVE second quarter revenues increase 40%

SANUWAVE second quarter revenues increase 40%

Lotus Tissue Repair to develop DEB protein replacement therapy with $26 million Series A financing

Lotus Tissue Repair to develop DEB protein replacement therapy with $26 million Series A financing

Derma Sciences announces $29 million financing

Derma Sciences announces $29 million financing

Derma Sciences to raise $29M through private placement

Derma Sciences to raise $29M through private placement

LWW sponsors 26th Annual Clinical Symposium on Advances in Skin & Wound Care

LWW sponsors 26th Annual Clinical Symposium on Advances in Skin & Wound Care

Bharat Biotech announces the pricing for ROTAVAC vaccine

Bharat Biotech announces the pricing for ROTAVAC vaccine

Derma Sciences announces results of DSC127 Phase 2 trial in diabetic foot ulcers at 24-weeks

Derma Sciences announces results of DSC127 Phase 2 trial in diabetic foot ulcers at 24-weeks

Resection arthroplasty more effective for patients with diabetic foot ulcers

Resection arthroplasty more effective for patients with diabetic foot ulcers

CoDa Therapeutics raises $19.2 million in Series B financing

CoDa Therapeutics raises $19.2 million in Series B financing

ULURU fourth quarter net loss decreases to $0.3 million

ULURU fourth quarter net loss decreases to $0.3 million

Derma Sciences fourth quarter total sales increase 12% to record $15.3 million

Derma Sciences fourth quarter total sales increase 12% to record $15.3 million

DJO Global signs definitive agreement to purchase Rikco for $254.6 million

DJO Global signs definitive agreement to purchase Rikco for $254.6 million

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

Scientists receive HHS grant to investigate DSC127 in treatment of skin injuries linked with radiation exposure

Scientists receive HHS grant to investigate DSC127 in treatment of skin injuries linked with radiation exposure

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Sanofi-aventis, Sunnybrook enter agreement to develop and commercialize vasculotide

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

SANUWAVE Health raises $4,102,660 from exercise of Options

SANUWAVE Health raises $4,102,660 from exercise of Options

CVBT seeks FDA 'fast track' designation for CVBT-141B to treat ischemic diabetic wounds

CVBT seeks FDA 'fast track' designation for CVBT-141B to treat ischemic diabetic wounds

Positive results from Derma Sciences' Phase 2 trial with DSC127 in patients with diabetic foot ulcers

Positive results from Derma Sciences' Phase 2 trial with DSC127 in patients with diabetic foot ulcers